Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AutoImmune's salvage operation

After its Myloral and Colloral oral tolerance products failed to show statistically significant benefits to treat multiple sclerosis and rheumatoid arthritis, Autoimmune Inc. was forced to shut down operations. Nevertheless, the company is working to provide some returns to its investors, holding on to rights to

Read the full 466 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers